IDEAYA Biosciences Presents Positive Phase 1/2 Trial Results for IDE397 and Trodelvy in Rare Urothelial Cancer IDEAYA Biosciences reports promising results from a Phase 1/2 trial involving IDE397 and Trodelvy for patients with MTAP-deletion urothelial cancer. The study shows positive response rates, paving the way for further investigations.

IDEAYA Biosciences Presents Positive Phase 1/2 Trial Results for IDE397 and Trodelvy in Rare Urothelial Cancer #United_States #IDEAYA_Biosciences #South_San_Francisco #Trodelvy #IDE397

IDEAYA Biosciences Expands Phase 1/2 Study for Innovative Cancer Treatment with IDE397 and Trodelvy® IDEAYA Biosciences has commenced expanded Phase 1/2 trials for IDE397 combined with Trodelvy® to treat MTAP-deletion urothelial cancer, addressing significant medical needs.

IDEAYA Biosciences Expands Phase 1/2 Study for Innovative Cancer Treatment with IDE397 and Trodelvy® #United_States #IDEAYA_Biosciences #South_San_Francisco #Trodelvy #IDE397